- Trevena recently reported disappointing Q2 earnings that revealed they completely missed the Street's expectations and only pulled in ~$180K in revenue.
- The COVID-19 headwinds are slamming Trevena and the forecast does not appear to be clearing up. As a result, I believe investors need to be patient with TRVN.
- Despite the underwhelming earnings, the company reported some encouraging commercial trends that could bode well for the second half of 2021 and potentially establish some momentum in 2022.
- I discuss why I am remaining patient with my TRVN and how I intend to manage this position as the world continues to deal with the ongoing pandemic.
For further details see:
Trevena: Remaining Patient After A Disappointing Q2 Earnings